Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 17:17:42 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

IRLAB Therapeutics Q1’23 - Mesdopetam decision on the horizon

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

IRLAB Therapeutics Q1’23 - Mesdopetam decision on the horizon

2023-05-15 12:48:00

Redeye updates its view of IRLAB following the Q1 report. We argue that the future of Mesdopetam, and the decision made by Ipsen in this regard, will have a significant impact on the market sentiment towards IRLAB's stock in the coming months. Still, we argue that there is plenty of value in the company beyond Mesdopetam, including the independent asset Pirepemat (with phase IIb readout expected in 2024) and the research engine ISP.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/